ConcertAI has made a significant announcement, unveiling their new Accelerated Clinical Trials (ACT) platform. This innovative agentic AI tool is designed to substantially reduce both the timelines and costs associated with clinical trials, as stated by the company.
The ACT platform was created to address persistent issues that frequently impact clinical trials, including challenges in study design, patient enrollment, and clinical workflows. ConcertAI aims to streamline these facets significantly.
Utilizing ConcertAI’s multi-agent AI framework known as CARai, the ACT platform leverages a combination of real-world and proprietary data, along with predictive analytics. This integration leads to the development of advanced reasoning models that automate essential activities involved in trials.
“The CARAai platform serves as the foundation for Accelerated Clinical Trials, allowing our customers to swiftly integrate first-party and third-party data from sponsors, thereby enhancing agility and expertise within the clinical trial ecosystem,” stated Robert Zambon, Ph.D., Vice President of Product Management and Clinical Trial Solutions at ConcertAI, in an emailed statement.
CARAai is capable of connecting to public data sources like PubMed and ClinicalTrials.gov and can seamlessly integrate with popular trial management systems.
According to ConcertAI, the ACT platform has the potential to shorten overall trial timelines by 10 to 20 months, halve study design timelines, and significantly cut down on costly protocol changes.
“No other product on the market compares to [ACT],” Zambon emphasized. “Unlike other vendors, we’ve built purpose-specific clinical trial assistants within ACT, drawing from our extensive experience in this sector and training them using our proprietary model that includes 11 million curated patient records.”
This announcement comes shortly after Oracle launched its generative AI data tool, which aims to assist life sciences, medical device, and pharmaceutical companies in accelerating their research and development processes by utilizing real-world health data.
Both ConcertAI and Oracle will present their new AI platforms at this week’s SCOPE Summit in Orlando, Florida, according to the companies.
Alivia Kaylor is a scientist and the senior site editor of Pharma Life Sciences.
In summary, ConcertAI’s introduction of the Accelerated Clinical Trials platform represents a notable advancement in the clinical trial landscape. By leveraging cutting-edge AI technology, the platform promises to enhance efficiency and reduce costs, addressing long-standing challenges in the industry.
As innovation continues to transform the field of clinical research, both ConcertAI and Oracle are at the forefront, showcasing how data-driven solutions can lead to significant breakthroughs in trial management.
